- Home
- GNRC vs RDY Comparison
GNRC vs RDY Comparison
Compare GNRC & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- RDY
- Stock Information
- Founded
- GNRC 1959
- RDY 1984
- Country
- GNRC United States
- RDY India
- Employees
- GNRC N/A
- RDY N/A
- Industry
- GNRC Metal Fabrications
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- RDY Health Care
- Exchange
- GNRC Nasdaq
- RDY Nasdaq
- Market Cap
- GNRC 10.8B
- RDY 11.8B
- IPO Year
- GNRC 2010
- RDY N/A
- Fundamental
- Price
- GNRC $181.43
- RDY $14.86
- Analyst Decision
- GNRC Buy
- RDY Strong Buy
- Analyst Count
- GNRC 18
- RDY 2
- Target Price
- GNRC $179.33
- RDY $16.95
- AVG Volume (30 Days)
- GNRC 811.7K
- RDY 768.4K
- Earning Date
- GNRC 10-30-2025
- RDY 11-04-2025
- Dividend Yield
- GNRC N/A
- RDY 0.48%
- EPS Growth
- GNRC 54.62
- RDY 2.20
- EPS
- GNRC 6.03
- RDY 0.79
- Revenue
- GNRC $4,411,654,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- GNRC $5.66
- RDY $7.33
- Revenue Next Year
- GNRC $8.28
- RDY $1.96
- P/E Ratio
- GNRC $30.16
- RDY $18.77
- Revenue Growth
- GNRC 9.69
- RDY 15.86
- 52 Week Low
- GNRC $99.50
- RDY $12.26
- 52 Week High
- GNRC $203.25
- RDY $16.19
- Technical
- Relative Strength Index (RSI)
- GNRC 47.24
- RDY 64.75
- Support Level
- GNRC $179.69
- RDY $14.60
- Resistance Level
- GNRC $192.72
- RDY $14.85
- Average True Range (ATR)
- GNRC 4.71
- RDY 0.16
- MACD
- GNRC -1.00
- RDY 0.06
- Stochastic Oscillator
- GNRC 39.61
- RDY 80.20
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.